Frencken Group (E28) Lifts 3Q25 Revenue By 6.5%, Maintains Full-Year Growth Outlook

SGX Filings11-17

Frencken Group Limited (E28) announced on Nov, 17 2025 that revenue for the three months ended Sep, 30 2025 rose 6.5 % year-on-year to 211.5 million Singapore dollars, supported by higher contributions from its Mechatronics Division and stable sales in the IMS Division. Net profit attributable to shareholders increased 7.5 % to 9.9 million Singapore dollars, while gross profit margin improved to 14.8 % from 14.0 % a year earlier.

For the nine-month period to Sep, 30 2025, group revenue climbed 12.5 % to 642.8 million Singapore dollars and net profit grew 9.1 % to 29.8 million Singapore dollars. Gross profit margin for the nine months remained broadly stable at 14.3 %.

Within the Mechatronics Division, third-quarter revenue from the semiconductor segment increased 8.1 % to 99.1 million Singapore dollars, the medical segment rose 6.2 % to 31.7 million Singapore dollars and the industrial automation segment jumped 51.1 % to 13.5 million Singapore dollars. Revenue from the analytical life sciences segment declined 8.3 % to 41.0 million Singapore dollars. The IMS Division posted marginally higher revenue of 21.5 million Singapore dollars, with automotive sales at 15.7 million Singapore dollars and consumer and industrial electronics sales at 4.4 million Singapore dollars.

As of Sep, 30 2025, Frencken held total assets of 729.9 million Singapore dollars, cash and equivalents of 149.3 million Singapore dollars and total borrowings of 50.3 million Singapore dollars. Net cash stood at 99.0 million Singapore dollars, translating to a debt-to-equity ratio of about 11 %. Net asset value was 1.07 Singapore dollars per share.

Management expects group revenue for the second half of 2025 to be marginally lower than the first half, but still anticipates revenue growth for the full year 2025 compared with 2024. By segment, the semiconductor and industrial automation businesses are forecast to post higher full-year revenue, medical is expected to remain stable to higher, analytical life sciences is projected to be lower, and automotive is predicted to be stable.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment